1311285-11-6 Usage
Molecular structure
1-methyl-3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-pyrazole consists of a pyrazole ring, a methyl group, a substituted phenyl group, and a 1,3,2-dioxaborolan-2-yl group.
Pyrazole ring
A five-membered heterocyclic ring with one nitrogen atom and one carbon atom in the 1 and 3 positions, respectively.
Methyl group
A CH3 functional group attached to the pyrazole ring, contributing to the molecular structure's complexity.
Substituted phenyl group
A phenyl group (a six-membered carbon ring with delocalized pi electrons) attached to the pyrazole ring, with additional substituents.
1,3,2-dioxaborolan-2-yl group
A group with the formula O2B(O)C6H3, attached to the phenyl ring, adding further complexity to the molecule.
Potential applications
Due to its unique structure, this chemical compound may have potential uses in various fields, such as pharmaceuticals, materials science, or catalysis.
Further study required
The properties and potential uses of 1-methyl-3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-pyrazole are not yet fully understood and would require additional research to explore its possibilities.
Check Digit Verification of cas no
The CAS Registry Mumber 1311285-11-6 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,1,1,2,8 and 5 respectively; the second part has 2 digits, 1 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1311285-11:
(9*1)+(8*3)+(7*1)+(6*1)+(5*2)+(4*8)+(3*5)+(2*1)+(1*1)=106
106 % 10 = 6
So 1311285-11-6 is a valid CAS Registry Number.
1311285-11-6Relevant articles and documents
PYRIMIDINE PYRAZOLYL DERIVATIVES AND THEIR USE AS IRAK INHIBITORS
-
Page/Page column 82; 97; 116; 117; 119, (2015/07/23)
The present invention provides compounds of Formula (II) for the treatment of cancer, rheumatoid arthritis and other diseases.
TYROSINE KINASE INHIBITORS
-
Page/Page column 127; 128, (2011/08/03)
The present invention relates to pyridazin-4(1H)-one derivatives, that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosine kinase MET. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
NOVEL IRIDIUM COMPLEX AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME
-
, (2011/06/26)
A novel iridium complex includes a ligand including a phenyl ring and a pyrazole ring. The phenyl group is bonded to a triazine ring to form a backbone of the novel iridium complex. An organic light-emitting device includes the novel iridium complex.
NEW IRIDIUM COMPLEX AND ORGANIC LIGHT-EMITTING ELEMENT INCLUDING THE SAME
-
, (2011/06/26)
The present invention provides a novel iridium complex and an organic light-emitting element including the same. The novel iridium complex includes phenylpyrazole as a ligand and has a basic skeleton in which a pyrimidine ring is bonded to a phenyl ring.
